Five-Year Outcomes of Transcatheter or Surgical Aortic-Valve Replacement
- PMID: 31995682
- DOI: 10.1056/NEJMoa1910555
Five-Year Outcomes of Transcatheter or Surgical Aortic-Valve Replacement
Abstract
Background: There are scant data on long-term clinical outcomes and bioprosthetic-valve function after transcatheter aortic-valve replacement (TAVR) as compared with surgical aortic-valve replacement in patients with severe aortic stenosis and intermediate surgical risk.
Methods: We enrolled 2032 intermediate-risk patients with severe, symptomatic aortic stenosis at 57 centers. Patients were stratified according to intended transfemoral or transthoracic access (76.3% and 23.7%, respectively) and were randomly assigned to undergo either TAVR or surgical replacement. Clinical, echocardiographic, and health-status outcomes were followed for 5 years. The primary end point was death from any cause or disabling stroke.
Results: At 5 years, there was no significant difference in the incidence of death from any cause or disabling stroke between the TAVR group and the surgery group (47.9% and 43.4%, respectively; hazard ratio, 1.09; 95% confidence interval [CI], 0.95 to 1.25; P = 0.21). Results were similar for the transfemoral-access cohort (44.5% and 42.0%, respectively; hazard ratio, 1.02; 95% CI, 0.87 to 1.20), but the incidence of death or disabling stroke was higher after TAVR than after surgery in the transthoracic-access cohort (59.3% vs. 48.3%; hazard ratio, 1.32; 95% CI, 1.02 to 1.71). At 5 years, more patients in the TAVR group than in the surgery group had at least mild paravalvular aortic regurgitation (33.3% vs. 6.3%). Repeat hospitalizations were more frequent after TAVR than after surgery (33.3% vs. 25.2%), as were aortic-valve reinterventions (3.2% vs. 0.8%). Improvement in health status at 5 years was similar for TAVR and surgery.
Conclusions: Among patients with aortic stenosis who were at intermediate surgical risk, there was no significant difference in the incidence of death or disabling stroke at 5 years after TAVR as compared with surgical aortic-valve replacement. (Funded by Edwards Lifesciences; PARTNER 2 ClinicalTrials.gov number, NCT01314313.).
Copyright © 2020 Massachusetts Medical Society.
Comment in
-
TAVR at 5 Years - Rematch or Swan Song for Surgery?N Engl J Med. 2020 Feb 27;382(9):867-868. doi: 10.1056/NEJMe2000240. N Engl J Med. 2020. PMID: 32101670 No abstract available.
-
Five-Year Outcomes with Transcatheter Aortic-Valve Replacement.N Engl J Med. 2020 Aug 6;383(6):594. doi: 10.1056/NEJMc2018853. N Engl J Med. 2020. PMID: 32757530 No abstract available.
-
Five-Year Outcomes with Transcatheter Aortic-Valve Replacement.N Engl J Med. 2020 Aug 6;383(6):594-595. doi: 10.1056/NEJMc2018853. N Engl J Med. 2020. PMID: 32757531 No abstract available.
-
Revalving to treat transcatheter valve failure.Lancet. 2023 Oct 28;402(10412):1500-1501. doi: 10.1016/S0140-6736(23)01735-X. Epub 2023 Aug 31. Lancet. 2023. PMID: 37660718 No abstract available.
Publication types
MeSH terms
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical